Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Recap

MDGL Q1 2026 May 7, 2026

Get alerts when MDGL reports next quarter

The stock gained 6.4% post-earnings, reflecting investor approval of strong net sales growth driven by accelerating Rezdiffra adoption and a rapidly expanding addressable market in MASH.

Earnings Per Share Beat

$-3.25 vs $-3.61 est.

+10.0% surprise

Revenue Beat

311337000 vs 301054300 est.

+3.4% surprise

Market Reaction

1-Day -4.64%

5-Day -4.6%

See MDGL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q1 2026 net sales reached $311 million, up 127% year-over-year.
Active Rezdiffra patients grew to over 42,250, a 2.5x increase from Q1 2025.
The U.S. diagnosed MASH market expanded nearly 50% since 2023, now estimated at 460,000 patients.
Rezdiffra penetration remains below 10%, underscoring significant runway ahead.
Management highlighted a robust data generation strategy with upcoming presentations reinforcing efficacy and cardiovascular risk benefits.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MDGL on AllInvestView.